Hester Biosciences informs about outcome of board meeting

11 Mar 2026 Evaluate
Hester Biosciences has informed that the Board of Directors at the meeting held on 11 March 2026, and on the recommendations of the Audit Committee of the Board, considered and approved the Divestment of 43.81% equity shareholding out of total 54.81% in its subsidiary, Texas Lifesciences (TLPL), by way of transfer/sale of shares to the existing promoter shareholders of the TLPL. TLPL is not material subsidiary of the Company. TLPL will ceased to be the subsidiary of the Company upon completion share transfer transaction as above. The Board Meeting commenced at 10:46 am (IST) and concluded at 11:05 am (IST).

The above information is a part of company’s filings submitted to BSE.

Hester Biosciences Share Price

1443.50 -8.95 (-0.62%)
11-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.90
Dr. Reddys Lab 1325.50
Cipla 1329.90
Zydus Lifesciences 922.00
Lupin 2345.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×